ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-β pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis

American Journal of Pathology

Volumn 165, Issue 4, 2004, Pages 1413-1422

  Fagan, Anne M ^a   Christopher, Erin ^a   Taylor, Jennie W ^a   Parsadanian, Maia ^a   Spinner, Michael ^a   Watson, Melanie ^a   Fryer, John D ^a   Wahrle, Suzanne ^a   Bales, Kelly R ^b   Paul, Steven M ^b,c   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ADOLESCENT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE LIKE BRAIN AMYLOIDOSIS; AMYLOIDOSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC MANIPULATION; HYPERCHOLESTEROLEMIA; LIPID BRAIN LEVEL; LIPOPROTEIN DEFICIENCY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PDAPP GENE; PRIORITY JOURNAL; PROTEIN METABOLISM; TRANSGENIC MOUSE;

EID: 4644269609     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63399-8     Document Type: Article

References (77)

1. Jarvik J, Wijsman E, Kukuli W, Schellenberg G, Yu C, Larson E: Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995, 45:1092-1096
2. Kalmijn S, Launer L, Ott A, Witteman J, Hofman A, Breteler M: Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997, 42:776-782
3. Kuo Y, Emmerling M, Bisgaier C, Essenburg A, Lampert H, Drumm D, Roher A: Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ1-42 levels. Biochem Biophys Res Commun 1998, 252:711-715
4. Notkola I, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A: Serum cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiol 1998, 17:14-20
5. Romas S, Tang M, Berglund L, Mayeux R: APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999, 53:517-521
6. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8:1-21
7. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:1977-1981
8. Pastor P, Roe C, Villegas A, Bedoya G, Chakraverty S, Garcia G, Tirado V, Norton J, Rios S, Martinez M, Kosik K, Lopera F, Goate A: Apolipoprotein E ε4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol 2003, 54:163-169
9. Deb S, Braganza J, Norton N, Williams H, Kehoe P, Williams J, Owen M: APOE epsilon 4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. Br J Psychiatry 2000, 177:469-470
10. Wolozin B, Kellman W, Ruosseau P, Celesia G, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439-1443
11. Jick H, Zornberg G, Jick S, Seshadri S, Drachman D: Statins and the risk of dementia. Lancet 2000, 356:1627-1631
12. Mori T, Paris D, Town T, Rojiani A, Sparks D, Delledonne A, Crawford F, Abdullah L, Humphrey J, Dickson D, Mullan M: Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APPSW mice. J Neuropathol Exp Neurol 2001, 60:778-785
13. Koudinov A, Matsubara E, Frangione B, Ghiso J: The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994, 205:1164-1171
14. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J: Biochemical characterization of Alzheimer's soluble beta protein in human cerebrospinal fluid: association with high density lipoprotein. Biochem Biophys Res Commun 1996, 223:592-597
15. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M: Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 1999, 45:537-541
16. Fagan A, Younkin L, Morris J, Fryer J, Cole T, Younkin S, Holtzman D: Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000, 48:201-210
17. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti C: Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998, 95:6460-6464
18. Frears E, Stephens D, Walters C, Davies H, Austen B: The role of cholesterol in the biosynthesis of β-amyloid. NeuroReport 1999, 10:1699-1705
19. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, Von Bergmann K, Hennerici M, Beyreuther K, Hartmann T: Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001, 98:5856-5861
20. Sparks D, Liu H, Gross D, Scheff S: Increased density of cortical apolipoprotein E immunoreactive neurons in rabbit brain after dietary administration of cholesterol. Neurosci Lett 1995, 187:142-144
21. Howland D, Trusko S, Savage M, Reaume A, Lang D, Hirsch JD, Maeda N, Siman R, Greenberg B, Scott R, Flood D: Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol. J Biol Chem 1998, 273:16576-16582
22. Refolo L, Pappolla M, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint G, Sambamurti K, Duff K: Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000, 7:321-331
23. swe transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J Nutr Health Aging 2002, 6:315-319
24. Refolo L, Pappolla M, LaFrancois J, Malester B, Schmidt S, Thomas-Bryant T, Tint G, Wang R, Mercken M, Petanceska S, Duff K: A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001, 8:890-899
25. Buxbaum J, Cullen E, Friedhoff L: Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer β-amyloid peptide in vitro and in patients. Front Biosci 2002, 7:a50-59
26. Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K: Treatment with Simvastatin in patients with Alzheimer's disease lowers both α- and β-cleaved amyloid precursor protein. Dement Geriatr Cognit Disord 2003, 16:25-30
27. Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, Walter S, Walter J, Brechtel K, Muehlhauser F, von Bergmann K, Lutjohann D: Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002, 59:1257-1258
28. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz J: Treatment with Simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002, 52:346-350
29. Sparks D, Kuo Y, Roher A, Martin T, Lukas R: Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations. Ann NY Acad Sci 2000, 903:335-344
30. Vaughan C, Murphy M, Buckley B: Statins do more than just lower cholesterol. Lancet 1996, 348:1079-1082
31. Williamson R, Lee D, Hagaman J, Maeda N: Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci USA 1992, 89:7134-7138
32. Plump A, Azrolan N, Odaka H, Wu L, Jiang X, Tall A, Eisenberg S, Breslow J: ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J Lipid Res 1997, 38:1033-1047
33. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995, 373:523-527
34. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM: Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J Clin Invest 1999, 103:R15-R21
35. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 1997, 17:263-264
36. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM: Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002, 81:229-236
37. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Hsiao-Ashe K, Irizarry MC, Hyman BT: ApoE is required for neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease. Ann Neurol 2000, 47:739-747
38. Cavalieri B: Geometria Degli Indivisibili. Torino, Unione Tipografico, 1966
39. West MJ: New stereological methods for counting neurons. Neurobiol Aging 1993, 14:275-285
40. Wozniak D, Brosnan-Watters G, Nardi A, McEwen M, Corso T, Olney J, Fix A: MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res 1996, 707:165-179
41. DeMattos R, O'Dell M, Parsadanian M, Taylor W, Harmony JK, Bales R, Paul S, Aronow B, Holtzman D: Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2002, 99:10843-10848
42. Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ, Fagan AM, Holtzman DM: GFAP-apoE transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci 1998, 18:3261-3272
43. Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA, LaDu MJ: Unique lipoproteins secreted by primary astrocytes from wild-type, apoE (-/-), and human apoE transgenic mice. J Biol Chem 1999, 274:30001-30007
44. Han X, Cheng H, Fryer J, Fagan A, Holtzman D: Novel role of apolipoprotein E in the central nervous system: modulation of sulfatide content. J Biol Chem 2003, 278:8043-8051
45. Krul ES, Tang J: Secretion of apolipoprotein E by an astrocytoma cell line. J Neurosci Res 1992, 32:227-238
46. Weiler-Guttler H, Sommerfeldt M, Papandrikopoulou A, Mischek U, Bonitz D, Frey A, Grupe M, Scheerer J, Gassen H: Synthesis of apolioprotein A-I in pig brain microvascular endothelial cells. J Neurochem 1990, 54:444-450
47. Mockel B, Zinke H, Flach R, Weib B, Weiler-Guttler H, Gassen H: Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J Neurochem 1994, 62:788-798
48. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L: Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1997, 94:1550-1555
49. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM: Human and murine apoE markedly influence Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 2002, 9:305-318
50. Avdulov NA, Chochina SV, Igbavboa U, Warden CS, Vassiliev AV, Wood WG: Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J Neurochem 1997, 69:1746-1752
51. Kakio A, Nishimoto S-I, Yanagisawa K, Kozutsumi Y, Matsuzaki K: Cholesterol-dependent formation of GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001, 276:24985-24990
52. Linton MF, Gish R, Hubl ST, Butler E, Esquivel C, Bry WI, Boyles JK, Wardell MR, Young SG: Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 1991, 88:270-281
53. Ma J, Yee A, Brewer HB, Das S, Potter H: Amyloid-associated proteins alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372:92-94
54. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B: Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J 1995, 306:599-604
55. Schmechel DE, Saunders AM, Strittmattter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:9649-9653
56. V717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999, 96:15233-15238
57. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM: Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000, 97:2892-2897
58. Carter DB, Dunn E, McKinley DD, Stratman NC, Boyle TP, Kuiper SL, Oostveen JA, Weaver RJ, Boller JA, Gurney ME: Human apolipoprotein E4 accelerates β-amyloid deposition in APPsw transgenic mouse brain. Ann Neurol 2001, 50:468-475
59. Huang Y, Zhu Y, Langer C, Raabe M, Wu S, Wiesenhutter B, Seedorf U, Maeda N, Assmann G, von Eckardstein A: Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal, apolipoprotein A-I-, and apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1997, 17:2010-2019
60. Li H, Reddick R, Maeda N: Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993, 1993:1814-1821
61. Hartmann T: Cholesterol, Aβ, and Alzheimer's disease. Trends Neurosci 2001, 24:S45-S48
62. Puglielli L, Tanzi R, Kovacs D: Alzheimer's disease: the cholesterol connection. Nature Neurosci 2003, 6:345-351
63. Gordon T, Castelli W, Hjortland M, Kannel W, Dawber T: High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977, 62:707-714
64. Reichl D, Miller N: Pathophysiology of reverse cholesterol transport: insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis 1989, 9:785-797
65. Norum R, Lakier J, Goldstein S, Angel A, Goldberg R, Block W, Noffze D, Dolphin P, Edelglass J, Bogorad D, Alaupovic P: Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med 1982, 306:1513-1519
66. Schaefer E, Heaton W, Wetzel M, Brewer HJ: Plasma apolipoprotein A-I absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982, 2:16-26
67. Karathanasis S, Zannis V, Breslow J: A DNA insertion in the apolipoprotein A-I gene of patients with premature atherosclerosis. Nature 1983, 305:823-825
68. Blue M, Ostapchuk P, Gordon J, Williams D: Synthesis of apolipoprotein AI by peripheral tissues of the rooster: a possible mechanism of cellular cholesterol efflux. J Biol Chem 1982, 257:11151-11159
69. Banerjee D, Mukherjee T, Redman C: Biosynthesis of high density lipoprotein by chicken liver: intracellular transport and proteolytic processing of nascent apolipoprotein A-I. J Cell Biol 1985, 101:1219-1226
70. Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ: Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem 1996, 66:2429-2435
71. Roheim PS, Carey M, Forte T, Vega GL: Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 1979, 76:4646-4649
72. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH: Lipoproteins and their receptors in the central nervous system. J Biol Chem 1987, 262:14352-14360
73. Merched A, Xia Y, Visvikis S, Serot J, Siest G: Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the seventy of Alzheimer's disease. Neurobiol Aging 2000, 21:27-30
74. Wu C, Liao P, Lin C, Kuo C, Chen S, Chen H, Kuo Y: Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. J Neural Transm 2003, 110:641-649
75. Naidu A, Xu Q, Catalano R, Cordell B: Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res 2002, 958:100-111
76. Petanceska S, Papolla M, Refolo L: Modulation of Alzheimer's amyloidosis by statins: mechanisms of action. Curr Med Chem Immunol Endosc Metab Agents 2003, 3:233-243
77. Eckert G, Kirsch C, Mueller W: Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. NeuroReport 2001, 12:883-887